Tempus AI has expanded its Tempus Next care pathway intelligence platform to include breast cancer, adding to its existing lung cancer capabilities. The AI-enabled platform integrates patient electronic medical record data with clinical guidelines to help physicians identify care gaps and deliver guideline-directed medical care.
Since launching in 2024, Tempus Next has screened thousands of patients across its provider network for lung cancer care gaps. The breast cancer expansion targets five different biomarker testing gaps specific to the disease, supporting physicians in delivering guideline-based care to eligible patients.
The platform addresses challenges healthcare providers face in keeping current with rapidly evolving clinical guidelines, particularly around biomarker testing such as ESR1 mutations in metastatic breast cancer. Tempus Next integrates multimodal data from patient EMRs with updated clinical guidelines to surface care gaps and identify patients who may benefit from guideline-recommended testing.
Mercy, a health system with over 1,000 physician practice locations across Arkansas, Illinois, Kansas, Missouri, and Oklahoma, has integrated Tempus Next for both breast and lung cancer into its EMR system. The health system serves patients through more than 5,000 physicians and advanced practitioners.
“Staying current with rapidly evolving clinical guidelines—especially regarding biomarker testing like ESR1 mutations in metastatic breast cancer—remains a challenge for healthcare providers everywhere,” said Dr. Jay Carlson, Medical Director of Oncology and Clinical Chair of Mercy Research. “Tools like Tempus Next support our team in identifying patients who may benefit from guideline-recommended testing.”
The platform aims to support community oncologists who serve large patient volumes and face challenges keeping pace with complex, rapidly changing clinical guidelines. Tempus positions the technology as meeting providers where they are through custom integrations designed to facilitate optimized care delivery.
“Keeping up with the complex and rapidly evolving clinical guidelines is a nearly impossible task for physicians, especially those in the community setting,” said Chris Scotto DiVetta, Senior Vice President of AI Applications at Tempus.
The development of Tempus Next’s breast cancer module was funded by Tempus and life sciences company sponsors. The expansion builds on Tempus’s library of multimodal data and AI-enabled precision medicine solutions designed to provide personalized patient care recommendations.
